Table 3. Efficacy and impact of SMC against malaria, parasitaemia, gametocyte carriage, anaemia, and deaths, in each age group.

Outcome	CCM	SMC+CCM	Efficacy (95% CI)	Difference‡ (95% CI)
Children <5 years (aged 3–59 months at cycle 1)
Malaria cases, rate/1,000 (cases/1,000s of person-months)*	134.6 (797/5.92)	23.8 (145/6.10)	82% (71%, 89%)	110.8 (64.7, 156.8), p < 0.001
Prevalence of parasitaemia†	18%	5.7%	69% (42%, 83%)	12.5% (6.8%, 18.2%), p < 0.001
Gametocyte carriage†	3.5%	1.1%	69% (−2.1%, 91%)	2.45% (−0.6%, 5.5%), p = 0.105
Mean Hb, g/l†	94	101		7 (2, 11), p = 0.007
Anaemia (Hb < 110 g/l)†	77.4%	68.4%	12% (0.0%, 22%)	9.1% (0.6%, 17.5%), p = 0.037
Severe anaemia (Hb < 60 g/l)†	3.3%	0.81%	75% (13%, 93%)	2.5% (0.2%, 5.0%), p = 0.036
Deaths from all causes, rate/1,000 (deaths/1,000s of person-months)*	1.87 (11/5.92)	1.98 (12/6.10)		−0.11 (−2.0, 1.8)
Children 5–9 years (aged 60–119 months at cycle 1)
Malaria cases, rate/1,000 (cases/1,000s of person-months)*	121.6 (675/5.55)	20.2 (125/6.17)	83% (76%, 89%)	101.3 (66.7, 136.0), p < 0.001
Prevalence of parasitaemia†	25%	5.8%	77% (53%, 89%)	19.3% (8.3%, 30.2%), p = 0.001
Gametocyte carriage†	2.1%	1.2%	44% (−115%, 86%)	0.9% (−1.0%, 2.8%), p = 0.327
Mean Hb, g/l†	109	114		5.2 (0.4, 9.9), p = 0.035
Anaemia (Hb < 110 g/l)†	47.5%	33.4%	30% (5.4%, 48%)	14.1% (3.1%, 25.0%), p = 0.014
Severe anaemia (Hb < 60 g/l)†	2.1%	1.7%	16% (−224%, 78%)	0.3% (−2.1%, 2.8%), p = 0.778
Deaths from all causes, rate/1,000 (deaths/1,000s of person-months)*	0.18 (1/5.55)	0.32 (2/6.17)		−0.14 (−0.66, 0.37)

^‡Difference: CCM − SMC+CCM.

*Confirmed cases or deaths per 1,000 child-months (number of cases or deaths/1,000s of child-months) for July–November 2011.

^†Measured at the end of the transmission season.

CCM, community case management; Hb, haemoglobin; SMC, seasonal malaria chemoprevention.